Compare StocksHCA vs JNJ

HCA Healthcare, Inc. (HCA) vs Johnson & Johnson (JNJ): Which Is the Better Buy in 2026?

As of 2026-06-21, HCA is undervalued at $375, with a DCF intrinsic value of $523 and a margin of safety of 28%. JNJ is fairly valued at $228, with an intrinsic value of $281 and a margin of safety of 19%. Of the two, HCA has the wider margin of safety.

HCA
HCA Healthcare, Inc.
$375.17
VS
JNJ
Johnson & Johnson
$228.39

Rewards

HCA
  • HCA Healthcare, Inc. has maintained ROIC above 15% for 4 consecutive years, indicating a durable competitive advantage.
  • HCA Healthcare, Inc. scores 95/100 on the Economic Moat Score (Wide Moat), with roic consistency as the strongest competitive dimension.
  • Free cash flow has grown at a 23.1% CAGR over the past 4 years, demonstrating strong earnings power growth.
JNJ
  • Johnson & Johnson has maintained ROIC above 15% for 4 consecutive years, indicating a durable competitive advantage.
  • Gross margin of 68.0% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • Johnson & Johnson scores 90/100 on the Economic Moat Score (Wide Moat), with revenue predictability as the strongest competitive dimension.

Risks

HCA
    JNJ
    • Trailing P/E of 26.5x is 33% above the historical average of 20.0x — the stock trades at a premium to its own history.
    • PEG ratio of 2.97 indicates the stock is expensive relative to its expected growth — the market may be pricing in more growth than analysts project.
    • Insiders have sold $2.4M worth of stock in the past 3 months — significant insider liquidation.

    Key Valuation Metrics

    Learn more →
    HCA
    JNJ
    Valuation
    $7.69B
    Free Cash Flow
    $19.31B
    9.24%
    FCF Yield
    3.51%
    12.92
    Trailing P/E
    26.46
    11.33
    Forward P/E
    17.96
    Quality & Moat
    18.14%
    ROIC
    15.32%
    N/A
    ROE
    26.42%
    41.61%
    Gross Margin
    68.04%
    1.13
    PEG Ratio
    2.97
    Balance Sheet Safety
    N/A
    Net Debt / Equity
    0.41
    N/A
    Interest Coverage
    N/A
    3.13
    Net Debt / EBITDA
    0.96
    0.83%
    Dividend Yield
    2.35%
    HCA: 5Ties: 1JNJ: 4
    HCAJNJ

    Historical Fundamentals

    Learn more →
    HCA

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    JNJ

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

    $1 Retained Earnings Test

    Learn more →
    HCA
    $2.43
    created per $1 retained over 3 years
    Exceptional Value Creator
    Σ Retained
    $15.76B
    Δ Market Cap
    +$38.30B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
    JNJ
    $0.91
    created per $1 retained over 3 years
    Mediocre Allocator
    Σ Retained
    $40.05B
    Δ Market Cap
    +$36.63B
    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
    > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

    Discounted Cash Flow (DCF) Analysis

    Learn more →
    HCA
    28.2% Margin of Safety
    Price is 28.2% below estimated fair value
    Current Price: $375.17
    Fair Value: $522.55
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued
    JNJ
    18.6% Margin of Safety
    Price is 18.6% below estimated fair value
    Current Price: $228.39
    Fair Value: $280.51
    Strongly undervalued
    Undervalued
    Fairly valued
    Overvalued
    Strongly overvalued

    Reverse DCF — Market-Implied Growth

    Learn more →
    HCA

    What growth rate is the market pricing in at $375?

    +7.3%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +5.6%

    The market implies +7.3% Owner Earnings growth, roughly in line with history — reasonably priced.

    Standard FCF implies +5.6%, reflecting ongoing growth investment.

    JNJ

    What growth rate is the market pricing in at $228?

    +7.7%
    Market-Implied Owner Earnings Growth
    Standard FCF implies +13.3%

    The market implies +7.7% Owner Earnings growth, above historical trends.

    Standard FCF implies a demanding +13.3%, reflecting heavy growth investment.

    Economic Moat Score

    Learn more →
    HCA
    95/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat with strength across all dimensions. ROIC Consistency is the standout factor.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.
    JNJ
    90/100
    Wide Moat
    70+ Wide · 40-69 Narrow · <40 None

    Wide moat with strength across all dimensions. Revenue Predictability is the standout factor.

    Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

    Forensic Accounting

    Learn more →
    HCA
    -2.78
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
    JNJ
    -2.31
    Unlikely Manipulator
    Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

    M-Score Trend

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

    Ownership Breakdown

    Learn more →
    HCA
    Insiders 16.2%Institutions 78.3%Retail & Other 5.5%
    No. of Institutional Holders1,953
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
    JNJ
    Insiders 0.1%Institutions 76.9%Retail & Other 23.1%
    No. of Institutional Holders5,730
    High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

    High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

    Insider Buying Activity

    Learn more →
    HCA
    0
    Buys (3M)
    0
    Buys (12M)
    No open market insider purchases found.
    Open market purchases · includes direct & indirect ownership · excludes option exercises
    JNJ
    0
    Buys (3M)
    1
    Buys (12M)
    Total value (12M): $257,688
    MORIKIS JOHN G
    Director
    $257,688
    @ $206.15 · 2025-11-26
    WEINBERGER MARK A
    Director
    $147,220
    @ $147.22 · 2024-12-12
    Open market purchases · includes direct & indirect ownership · excludes option exercises

    Open market purchases · includes direct & indirect ownership · excludes option exercises.

    Insider Selling Activity

    Learn more →
    HCA
    0
    Sells (3M)
    7
    Sells (12M)
    Total value (12M): $32.73M
    MCALEVEY MICHAEL R.
    Officer
    $903,537
    @ $533.37 · 2026-02-18
    WYATT CHRISTOPHER F
    Officer
    $2.02M
    @ $505.00 · 2026-02-11
    BERRES JENNIFER
    Officer
    $4.13M
    @ $514.58 · 2026-02-11
    CUFFE MICHAEL S
    Officer
    $747,135
    @ $498.09 · 2026-02-03
    HAZEN SAMUEL N
    Chief Executive Officer
    $21.48M
    @ $501.04 · 2026-02-03
    MCALEVEY MICHAEL R.
    Officer
    $1.84M
    @ $473.79 · 2025-11-05
    CUFFE MICHAEL S
    Officer
    $1.61M
    @ $418.84 · 2025-09-08
    FOSTER JON MARK
    Officer
    $5.80M
    @ $369.32 · 2025-05-13
    BERRES JENNIFER
    Officer
    $3.08M
    @ $322.59 · 2025-02-14
    AKDAMAR EROL R
    Officer
    $1.02M
    @ $353.00 · 2024-11-14
    BILLINGTON PHILLIP G
    Officer
    $1.36M
    @ $350.00 · 2024-11-14
    WHALEN KATHLEEN M
    Officer
    $527,677
    @ $357.99 · 2024-11-14
    CUFFE MICHAEL S
    Officer
    $3.22M
    @ $385.42 · 2024-09-12
    WHALEN KATHLEEN M
    Officer
    $1.76M
    @ $362.13 · 2024-07-31
    WYATT CHRISTOPHER F
    Officer
    $1.44M
    @ $360.20 · 2024-07-29
    REINER DEBORAH M
    Officer
    $1.19M
    @ $359.96 · 2024-07-29
    TORRES KATHRYN A
    Officer
    $659,328
    @ $355.05 · 2024-07-25
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
    JNJ
    1
    Sells (3M)
    13
    Sells (12M)
    Total value (12M): $103.65M
    WENGEL KATHRYN E
    Chief Technology Officer
    $2.41M
    @ $241.15 · 2026-06-11
    DECKER ROBERT J
    Officer
    $1.01M
    @ $247.87 · 2026-02-27
    SCHMID TIMOTHY
    Officer
    $324,763
    @ $245.66 · 2026-02-20
    SCHMID TIMOTHY
    Officer
    $5.53M
    @ $244.33 · 2026-02-18
    REED JOHN C
    Officer
    $13.11M
    @ $243.00 · 2026-02-17
    WOLK JOSEPH J
    Chief Financial Officer
    $21.77M
    @ $242.80 · 2026-02-17
    SWANSON JAMES D
    Chief Technology Officer
    $15.11M
    @ $243.39 · 2026-02-17
    BROADHURST VANESSA
    Officer
    $1.51M
    @ $243.39 · 2026-02-17
    REED JOHN C
    Officer
    $4.19M
    @ $192.71 · 2025-10-17
    TAUBERT JENNIFER L
    Officer
    $10.04M
    @ $177.81 · 2025-09-04
    DUATO JOAQUIN BOIX
    Chief Executive Officer
    $22.55M
    @ $179.21 · 2025-08-22
    WOLK JOSEPH J
    Chief Financial Officer
    $2.98M
    @ $176.91 · 2025-08-15
    REED JOHN C
    Officer
    $3.13M
    @ $163.55 · 2025-07-17
    DECKER ROBERT J
    Officer
    $1.16M
    @ $165.88 · 2025-02-25
    SCHMID TIMOTHY
    Officer
    $62,928
    @ $156.15 · 2025-02-18
    WOLK JOSEPH J
    Chief Financial Officer
    $2.00M
    @ $153.89 · 2025-02-07
    DECKER ROBERT J
    Officer
    $930,113
    @ $165.06 · 2024-08-30
    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

    Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

    🎭 Mr. Market's Mood

    Learn more →
    HCA
    FearGreed
    😨Fear(39/100)

    "Market is pessimistic — investigate whether fears are temporary or structural"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
    JNJ
    FearGreed
    😏Greed(62/100)

    "Market is optimistic — be cautious and ensure you have a margin of safety"

    Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

    ⚖️ Buffett Signal

    Learn more →
    HCA
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Fear (39)
    JNJ
    Awaiting DCF Data

    The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

    DCF Margin of Safety: N/AMr. Market's Mood: Greed (62)
    View HCA Full AnalysisView JNJ Full Analysis

    Frequently Asked Questions: HCA vs JNJ

    Is HCA Healthcare, Inc. or Johnson & Johnson more undervalued in 2026?

    Based on our discounted cash flow model, HCA trades at a 28.2% margin of safety (intrinsic value $523 vs. price $375), compared to JNJ's 18.6% margin of safety (intrinsic $281 vs. $228).

    Which stock has a wider economic moat, HCA Healthcare, Inc. or Johnson & Johnson?

    HCA scores 95/100 (Wide moat), while JNJ scores 90/100 (Wide moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

    Is HCA Healthcare, Inc. in financial distress?

    HCA's Altman Z-Score of 2.7 places it in the Grey zone, signaling elevated bankruptcy risk. JNJ scores 3.5 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

    Which company has better free cash flow, HCA Healthcare, Inc. or Johnson & Johnson?

    HCA Healthcare, Inc. (HCA) generates a 9.2% free cash flow yield, compared to Johnson & Johnson's 3.5%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

    Which stock has higher return on invested capital, HCA Healthcare, Inc. or Johnson & Johnson?

    HCA earns 18.1% ROIC versus JNJ's 15.3%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.

    Which dividend is safer, HCA Healthcare, Inc.'s or Johnson & Johnson's?

    HCA's dividend earns a safety score of 94/100 (Very Safe), compared to JNJ's 79/100 (Safe). HCA has raised its dividend for 3 consecutive years.